Chronic Myeloid Leukemia

Ovarian cancer has the highest mortality rate of all gynecologic malignancy. The receptor tyrosine kinases (RTKs), including EGFR, ERBB2, PDGFR, VEGFR and MET, are activated in subsets of ovarian cancer, suggesting that these kinases might represent novel therapeutic targets. However, clinical trials have not or just partially shown benefit to ovarian cancers treated with EGFR, ERBB2, or PDGFR inhibitors. Despite multiple RTK activation in ovarian cancer pathogenesis, it is unclear whether transforming ac

Serum microRNAs have the potential to be valuable biomarkers of cancer. This investigation addresses two issues that impact their utility: a) appropriate normalization controls and b) whether their altered levels persist in patients who are clinically free of the disease.|Serum microRNAs have the potential to be valuable biomarkers of cancer. This investigation addresses two issues that impact their utility: a) appropriate normalization controls and b) whether their altered levels persist in patients who a

Oncogene is one of the worlds leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.

The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independenc

Tumor-associated macrophages (TAMs) are alternatively activated cells induced by interleukin-4 (IL-4)-releasing CD4+ T cells. TAMs promote breast cancer invasion and metastasis; however, the mechanisms underlying these interactions between macrophages and tumor cells that lead to cancer metastasis remain elusive. Previous studies have found microRNAs (miRNAs) circulating in the peripheral blood and have identified microvesicles, or exosomes, as mediators of cell-cell communication. Therefore, one alternat

Detailed Description:. OBJECTIVES:. Primary. Determine the dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic

adult acute myeloid leukemia in remission. atypical chronic myeloid leukemia, BCR-ABL1 negative. ... childhood acute myeloid leukemia in remission. childhood chronic myelogenous leukemia. chronic eosinophilic leukemia.

Acute Myeloid Leukemia. Chronic Lymphocytic Leukemia. Chronic Myelogenous Leukemia. Study Type:. ... Leukemia, Myeloid, Acute. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Hematologic Neoplasms.

Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia ( STIM). ... Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Chronic Disease. Neoplasms by Histologic Type.

serial number protocol ICSG/CML/022) in patients with Ph+ chronic myeloid leukemia ( CML) in chronic phase ( CP) previously untreated, at high Sokal risk. ... CML022. Additional relevant MeSH terms:. Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous,